Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Lifted by McAdam LLC

McAdam LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 5.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,768 shares of the company’s stock after buying an additional 562 shares during the period. McAdam LLC’s holdings in Moderna were worth $489,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Axiom Advisory LLC grew its position in shares of Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock worth $847,000 after acquiring an additional 198 shares during the last quarter. Arkadios Wealth Advisors grew its position in Moderna by 2.2% in the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC increased its stake in shares of Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares during the period. Stephens Inc. AR raised its holdings in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the last quarter. Finally, Mather Group LLC. boosted its position in shares of Moderna by 25.7% during the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after buying an additional 262 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $39.42 on Monday. The stock’s 50-day moving average is $40.89 and its two-hundred day moving average is $60.43. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a fifty-two week low of $31.94 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the firm earned ($1.39) EPS. The company’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts anticipate that Moderna, Inc. will post -9.18 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Insiders own 15.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America reaffirmed an “underperform” rating and set a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, November 8th. Evercore ISI lowered their target price on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research note on Monday, January 27th. Jefferies Financial Group dropped their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Finally, HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $67.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.